C-N -0.21 MFC-T -0.13 BN-T -0.43 CGI-T -0.12 ARDT-N -0.22 AC-T -0.37 NGG-N -1.18
Labopharm Inc (DDS-T)

Labopharm Inc (DDS-T)

2 watching

0.00
0.00 (0.00%) 1d
0

Related posts

Nervous markets await Nvidia
HOLD

Labopharm Inc(DDS-T)

Jan 08, 2009
Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.
Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Unknown
Unlock Rating
$1.830

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

Dec 14, 2007
Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.
Peter HodsonPeter Hodson
No
Unlock Rating
$1.070

Stock price when the opinion was issued

biotechnology pharmaceutical
SELL

Labopharm Inc(DDS-T)

Nov 15, 2007
Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.
Lesley MarksLesley Marks
No
Unlock Rating
$1.230

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Labopharm Inc(DDS-T)

Nov 06, 2006
Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.
Chyanne FickesChyanne Fickes
Unknown
Unlock Rating
$5.560

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Labopharm Inc(DDS-T)

Oct 02, 2006
It is a small stock. Believes it will be a winner.
Chyanne FickesChyanne Fickes
No
Unlock Rating
$5.830

Stock price when the opinion was issued

biotechnology pharmaceutical
WATCH

Labopharm Inc(DDS-T)

Aug 23, 2005
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
Peter HodsonPeter Hodson
No
Unlock Rating
$4.890

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

Jan 17, 2005
Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.
Andrew McCreathAndrew McCreath
No
Unlock Rating
$4.170

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

Jan 17, 2005
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
David BaskinDavid Baskin
No
Unlock Rating
$4.170

Stock price when the opinion was issued

biotechnology pharmaceutical
WATCH

Labopharm Inc(DDS-T)

Aug 26, 2004
Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
Unknown
Unlock Rating
$4.030

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

May 17, 2004
Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.
Peter HodsonPeter Hodson
No
Unlock Rating
$4.090

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

May 29, 2003
Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.
Andrew McCreathAndrew McCreath
Unknown
Unlock Rating
$5.180

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

May 17, 2002
Volatile. Too few projects on the go. Risky.
Bruce CooperBruce Cooper
Unknown
Unlock Rating
$5.340

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

May 02, 2002
Interesting technology. Future is unclear. Risky.
Bruce CooperBruce Cooper
Unknown
Unlock Rating
$4.750

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Labopharm Inc(DDS-T)

Apr 01, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
Unknown
Unlock Rating
$5.800

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Labopharm Inc(DDS-T)

Mar 15, 2002
Speculative and risky. In a competitive sector.
Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Unknown
Unlock Rating
$5.380

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 15 of 28 entries
Next PageNext Page

Labopharm Inc(DDS-T) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Labopharm Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Labopharm Inc(DDS-T) Frequently Asked Questions

What is Labopharm Inc stock symbol?

Labopharm Inc is a OTC stock, trading under the symbol DDS-T on the (). It is usually referred to as or DDS-T

Is Labopharm Inc a buy or a sell?

In the last year, there was no coverage of Labopharm Inc published on Stockchase.

Is Labopharm Inc a good investment or a top pick?

Labopharm Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Labopharm Inc.

Why is Labopharm Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Labopharm Inc worth watching?

In the last year, there was no coverage of Labopharm Inc published on Stockchase.

What is Labopharm Inc stock price?

On , Labopharm Inc (DDS-T) stock closed at a price of $.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

FFH-T 33.09$2335.08
RCI.B-… 0.15$36.84
POW-T 1.38$53.11
T-T 0.11$22.48
GPS-N -5.64$22.31

Today's Top Picks

C-N -0.21$75.32
MFC-T -0.13$43.7
BN-T -0.43$79.25
CGI-T -0.12$37.71
ARDT-N -0.22$14.48

Popular Articles

Latest Sell Signals

XOM-N -0.39$102.3
CLS-T -1.82$158.92
ASML-Q -10.295$736.77
LRCX-Q -3.37$80.79
TXN-Q -2.14$182.85

Most Recent Experts

Greg Newman

Greg Newman

Scotia Wealth Management

Stockchase Insights

Stockchase Insights

5i Research

Shane Obata

Shane Obata

Middlefield Capital

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Andrew Pyle

Andrew Pyle

The Pyle Group, Scotia Wealth Mgt.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica